Pain Therapeutics Down 42% Pre-Market on FDA Rejection

by Benzinga Staff
June 24, 2011 7:54 AM | 12 seconds read |
Pain Therapeutics PTIE is down 42% pre-market on the reports that FDA rejected company's new painkiller. The stock is currently halted on pending news. Pain Therapeutics was trading at $5.35 pre-market before the trading halt..
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Pre-Market OutlookHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!